SCHEMBL1001675

SCHEMBL1001675

Cc1ccc(NC(=O)c2cccc(S(=O)(=O)N3CCCCC3)c2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.83
MEN1 O00255 4/20 0.81
KMT2A Q03164 4/20 0.81
SMN1; SMN2 Q16637 4/20 0.80
ALDH1A1 P00352 3/20 0.80
TDP1 Q9NUW8 1/20 0.77
GAA P10253 3/20 0.76
MAPK1 P28482 2/20 0.76
LMNA P02545 1/20 0.76
CYP1A2 P05177 1/20 0.74
CYP3A4 P08684 1/20 0.74
CYP2C9 P11712 1/20 0.74
MAPT P10636 2/20 0.72
TSHR P16473 1/20 0.72
NPC1 O15118 1/20 0.71
RAB9A P51151 1/20 0.71
KDM4E B2RXH2 1/20 0.71
CNR1 P21554 1/20 0.70
SIRT2 Q8IXJ6 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14291945 0.92 MEN1 (0.83) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL1002260 0.89 L3MBTL1 (0.85) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL1119369 0.89 ALDH1A1 (0.82) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL28912823 0.89 ALDH1A1 (0.82) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL1000557 0.89 ALDH1A1 (1.00) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL1095203 0.89 ALDH1A1 (1.00) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL22062413 0.88 MEN1 (0.78) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL13532172 0.88 KMT2A (0.76) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL13532150 0.88 SIRT2 (0.81) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL7821199 0.88 SMN1; SMN2 (0.84) L3MBTL1MEN1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280001-B1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD KK (JP) 2014-10-15 EP disclosed
US-8420823-B2 Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient MSD K.K. (JP) 2013-04-16 US disclosed
EP-2280001-A1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT Banyu Pharmaceutical Co., Ltd. (JP) 2011-02-02 EP disclosed
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD K.K. (JP) 2011-01-13 US disclosed
US-20100016310-A1 METHODS OF USING ARYL SULFONYL COMPOUNDS EFFECTIVE AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-01-21 US disclosed
WO-2008022171-A1 METHODS OF USING ARYL SULFONYL COMPOUNDS EFFECTIVE AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT ELOVL1, ELOVL6, ELOVL3 L3MBTL1 511/4885MEN1 4600/4885KMT2A 473/4885
US-20100016310-A1 METHODS OF USING ARYL SULFONYL COMPOUNDS EFFECTIVE AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS EPHX1, EPHX2, NCEH1 L3MBTL1 3743/4885MEN1 4563/4885KMT2A 2861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.